Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02192879
Other study ID # Pro00042166
Secondary ID
Status Terminated
Phase N/A
First received July 11, 2014
Last updated June 1, 2016
Start date August 2014
Est. completion date May 2016

Study information

Verified date June 2016
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Internal Safety Monitoring Board
Study type Interventional

Clinical Trial Summary

This study aims to compare the efficacy and safety of three alternative methods of analgesia in patients undergoing complex liver resection surgery: 1) thoracic epidural analgesia (TEA), 2) continuous paravertebral block (PVB) with patient-controlled analgesia (PCA) and 3) patient-controlled analgesia (PCA) alone. Regional anesthesia techniques such as TEA and PVB may improve recovery and decrease postoperative pain scores in addition to other benefits such earlier return of bowel function and shortened length of hospital stay, although some practitioners have voiced concerns about the safety and efficacy of these techniques in patients after liver resection who may develop postoperative coagulation abnormalities. The investigators plan to enroll a total of 150 patients (adults >/= 18 years of age who meet study criteria) scheduled for complex liver resection surgery in this study, who will then be randomized into 50 patients per arm of the study (3 total arms). Postoperative pain scores will be collected in PACU and throughout the patient's hospital stay as well as routine blood tests including complete blood count, coagulation labs (PT/INR, aPTT) and serum creatinine to measure renal function. The study team will also collect additional data prospectively on all patients enrolled in the study; these parameters will include age, sex, type of operation performed, length of operation, volume of intraoperative blood loss, volume of intraoperative fluid administration including blood products, daily postoperative intravenous fluid administration, length of time to first feeding, day of epidural catheter removal, length of hospital stay and incidence of major postoperative complications (surgical, respiratory, cardiac, renal, etc.). Once primary and secondary data points are obtained, the data will undergo rigorous statistical analysis using the appropriate statistical techniques to determine the outcomes. The investigators propose that epidural and/or paravertebral analgesia may improve recovery times and decrease hospital length of stay, which would be beneficial for the patient as well as decrease hospital costs. In addition, if better postoperative pain management scores can be achieved with epidural or paravertebral analgesia, and no significant prolonged postoperative coagulopathy is associated with patients undergoing major hepatic resection surgical procedures, these regional analgesia strategies can be considered a safe option for pain management in this patient population.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Age >/= 18 years and </= 80 years

- Scheduled for elective hepatic resection surgery

Exclusion Criteria:

- Preexisting coagulopathy (INR >1.5)

- Spinal stenosis

- Local infection in area where catheter will be inserted

- Severe cardiovascular disease (NYHA Class III/IV)

- Severe pulmonary disease (FEV1 <50% of predicted value)

- Allergy or sensitivity to narcotics or local anesthetics

- BMI >45

- Inability to give informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Pain Management Strategies in Liver Resection Surgery

Intervention

Device:
thoracic epidural
Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
continuous paravertebral catheter
Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
Drug:
Patient-Controlled Analgesia
Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other adverse events associated with regional catheter placement Adverse events in the 2 arms with regional catheters (TEA and PVB) will be monitored for. The study is not powered for comparing relative safety, especially for very rare adverse events such as epidural hematoma, but we will collect data to help inform future larger scale studies. postoperatively until removal of regional catheter removed, with an average of 3 days up to 7 days Yes
Primary Change in Pain Scores at rest Post-operative pain scores at rest, as assessed by Pain Assessment Scales (Wong-Baker Faces Scale and Visual Analog Pain Scale (VAS)) will be the primary outcome measured. The investigators hypothesize that the TEA and PVB groups may have decreased pain scores over the PCA group. Pain scores will be collected per standard PACU protocol (every 60 minutes) and on the hospital ward at hours 2, 4, 6 and 12, and then daily until day 3 or when the epidural/paravertebral catheter is removed. postoperatively until regional catheter removed, with an expected average of 3 days and up to 7 days No
Secondary hospital length of stay Hospital length of stay will be recorded for each of the 3 groups to see if there is a statistical difference between groups. time to discharge after surgery, with an expected average of approximately 7-10 days, up to 6 weeks if complications arise No
Secondary Gastrointestinal recovery Postoperative return of bowel function and time to first feeding will be recorded for each of the 3 groups. The investigators hypothesize that if the TEA and/or PVB groups receive less systemic opioid, they may experience less constipation and thus have earlier bowel recovery as evidenced by return of bowel function and oral feeding. postoperatively until return of bowel function, up to 7 days No
Secondary cumulative postoperative opioid requirement Cumulative postoperative opioid use will be recorded for subjects in the 3 arms of the study. The investigators hypothesize that the TEA and/or PVB arms may show less opioid use over PCA. postpoperatively until regional catheter removed or subjects transitioned to an oral pain management regimen, an expected average of 3 days and up to 7 days No
Secondary incidence of major postoperative complication Major surgical, infectious, respiratory, cardiac, and renal complications will be recorded for subjects in each arm of the study. time to discharge after surgery, with an expected average of approximately 7-10 days, up to 6 weeks if complications arise Yes
Secondary Change in Pain Scores with coughing Post-operative pain scores with coughing, as assessed by Pain Assessment Scales (Wong-Baker Faces Scale and Visual Analog Pain Scale (VAS)) will be measured. The investigators hypothesize that the TEA and PVB groups may have decreased pain scores with coughing over the PCA group. postoperatively until regional catheter removed, with an expected average of 3 days and up to 7 days No